Eylea 2 MG/0.05 ML syringe 0.05ML
Ended Awarded Last action
- Contract number
- SPE2DR26FMEG9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $28,674
Award facts
- Contract value 100% obligated
- $28,674.24 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $28,674.24 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EYLEA 2 mg/0.05 mL syringes. The delivery order, issued on January 28, 2026, with an ultimate completion date of February 19, 2026, carries no set-aside designation, indicating the contractor competed on an unrestricted basis. This award represents a standalone delivery order issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to streamline pharmaceutical procurement across the Department of Defense.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain through demonstrated performance on the PPV-G GEN V platform, which authorizes the company to supply a comprehensive range of pharmaceuticals, biologics, and medical consumables to military healthcare facilities worldwide. The company's single-award IDC under this program, designated contract SPE2DR and valued at $499,999,999, extends through December 2036 and reflects DLA's confidence in the contractor's capability to fulfill diverse and specialized pharmaceutical requirements for Department of Defense healthcare operations globally. This specific delivery order for EYLEA, a specialty pharmaceutical product, exemplifies the types of critical medical supplies DMS Pharmaceutical Group regularly delivers to support military medical readiness.
Quick answers
Who was awarded contract SPE2DR26FMEG9?
SPE2DR26FMEG9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 28, 2026.
How much is contract SPE2DR26FMEG9 worth?
The government has obligated $28,674 on SPE2DR26FMEG9.
Is contract SPE2DR26FMEG9 an order under another contract?
Yes. SPE2DR26FMEG9 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMEG9 competed?
The extent of competition for SPE2DR26FMEG9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award